Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
334.75
-1.73 (-0.51%)
May 29, 2026, 12:01 PM EDT - Market open
Amgen Employees
Amgen had 31,500 employees as of December 31, 2025. The number of employees increased by 3,500 or 12.50% compared to the previous year.
Employees
31,500
Change (1Y)
3,500
Growth (1Y)
12.50%
Revenue / Employee
$1,181,587
Profits / Employee
$247,619
Market Cap
180.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 31,500 | 3,500 | 12.50% |
| Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
| Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
| Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
| Dec 31, 2021 | 24,200 | -100 | -0.41% |
| Dec 31, 2020 | 24,300 | 900 | 3.85% |
| Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
| Dec 31, 2018 | 21,500 | 700 | 3.37% |
| Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
| Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
| Dec 31, 2015 | 17,900 | 0 | - |
| Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
| Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
| Dec 31, 2012 | 18,000 | 200 | 1.12% |
| Dec 31, 2011 | 17,800 | 400 | 2.30% |
| Dec 31, 2010 | 17,400 | 200 | 1.16% |
| Dec 31, 2009 | 17,200 | 300 | 1.78% |
| Dec 31, 2008 | 16,900 | -600 | -3.43% |
| Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
| Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
| Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
| Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
| Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
| Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
| Dec 31, 2001 | 7,700 | 400 | 5.48% |
| Dec 31, 2000 | 7,300 | 900 | 14.06% |
| Dec 31, 1999 | 6,400 | 900 | 16.36% |
| Dec 31, 1998 | 5,500 | 192 | 3.62% |
| Dec 31, 1997 | 5,308 | 662 | 14.25% |
| Dec 31, 1996 | 4,646 | 600 | 14.83% |
| Dec 31, 1995 | 4,046 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
AMGN News
- 2 days ago - This Boring Income Portfolio Strategy Could Unlock 300%+ Upside - Forbes
- 2 days ago - Ember LifeSciences announces new strategic investments boosting Series A to $27M - PRNewsWire
- 8 days ago - Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths - WSJ
- 9 days ago - Amgen says CFO Peter Griffith to retire, names Dittrich as successor - Reuters
- 9 days ago - Amgen CFO Peter Griffith to retire, Thomas Dittrich to succeed - TheFly
- 9 days ago - AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH - PRNewsWire
- 13 days ago - Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports - Reuters
- 13 days ago - Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug. - WSJ